Atrium Innovations Inc ATBIF

GMP $30 target

[jfallenangel]

New Old Target nc C$30.00 • Atrium shares are down 11.5% over the last week on the back of disappointing news from its comps • We believe that the decline is unwarranted as industry fundamentals remain strong and our analysis concludes that competitor weakness is attributed to company-specific factors • With a leading position in the US (40,000 Healthcare Practitioners,14% market share) and established presence in Europe we believe that the strength of the H&N industry bodes well for Atrium • Based on the recent stock pullback we believe investors should revisit Atrium. We maintain our BUY recommendation and $30.00 target